Abstract

Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer with unclear underlying molecular mechanisms and limited effective treatments. Through single-cell transcriptomic analysis, we found that SOX11 is specifically expressed in neuroendocrine (NE) cell populations. Further studies confirmed that SOX11 promotes NE transdifferentiation in prostate cancer via CXCL10/CXCR3 activation, thereby enhancing the migration and invasion abilities of prostate cancer cells. These results suggest that SOX11 may play a central role in driving NEPC progression, which is expected to serve as a candidate factor for subsequent therapeutic exploration